NovoCure (NVCR) Income from Continuing Operations (2014 - 2026)
NovoCure recorded quarterly Income from Continuing Operations of 71138000.0 in Q1 2026, down 190.37% quarter-over-quarter from 24499000.0 in Q4 2025, and down 107.28% year-over-year from 976554008.8 in Q1 2025.
NovoCure's Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 71138000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 107.28% year-over-year to 71138000.0; the TTM figure through Mar 2026 stood at 173046000.0 (down 5.4% YoY), while the FY2025 annual figure was 136227000.0, up 19.21% from the prior year.
- Income from Continuing Operations came in at 71138000.0 for Q1 2026 at NovoCure, down from 24499000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4647000.0 in Q1 2022 to a low of 71138000.0 in Q1 2026.
- A 5-year average of 39739352.94 and a median of 37303000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 1041.83% in 2023 and jumped 62.84% in 2025, its largest moves.
- NovoCure's Income from Continuing Operations stood at 37303000.0 in 2022, then declined by 26.21% to 47079000.0 in 2023, then tumbled by 40.02% to 65922000.0 in 2024, then surged by 62.84% to 24499000.0 in 2025, then slumped by 190.37% to 71138000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 71138000.0, 24499000.0, and 37270000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 273.95 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 199.50 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 220.30 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -71.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -71.14 Mn |
| Dec 31, 2025 | -24.50 Mn |
| Sep 30, 2025 | -37.27 Mn |
| Jun 30, 2025 | -40.14 Mn |
| Mar 31, 2025 | -34.32 Mn |
| Dec 31, 2024 | -65.92 Mn |
| Sep 30, 2024 | -30.57 Mn |
| Jun 30, 2024 | -33.38 Mn |
| Mar 31, 2024 | -38.76 Mn |
| Dec 31, 2023 | -47.08 Mn |
| Sep 30, 2023 | -49.49 Mn |
| Jun 30, 2023 | -57.42 Mn |
| Mar 31, 2023 | -53.06 Mn |
| Dec 31, 2022 | -37.30 Mn |
| Sep 30, 2022 | -26.58 Mn |
| Jun 30, 2022 | -24.01 Mn |
| Mar 31, 2022 | -4.65 Mn |
| Dec 31, 2021 | -26.46 Mn |
| Sep 30, 2021 | -13.12 Mn |
| Jun 30, 2021 | -14.64 Mn |
| Mar 31, 2021 | -4.13 Mn |
| Dec 31, 2020 | 4.92 Mn |
| Sep 30, 2020 | 9.28 Mn |
| Jun 30, 2020 | 1.66 Mn |
| Mar 31, 2020 | 3.95 Mn |
| Dec 31, 2019 | 4.26 Mn |
| Sep 30, 2019 | 1.93 Mn |
| Jun 30, 2019 | -1.27 Mn |
| Mar 31, 2019 | -12.15 Mn |
| Dec 31, 2018 | -15.63 Mn |
| Sep 30, 2018 | -11.69 Mn |
| Jun 30, 2018 | -15.51 Mn |
| Mar 31, 2018 | -20.72 Mn |
| Dec 31, 2017 | -10.95 Mn |
| Sep 30, 2017 | -11.50 Mn |
| Jun 30, 2017 | -21.17 Mn |
| Mar 31, 2017 | -18.05 Mn |
| Dec 31, 2016 | 58.82 Mn |
| Sep 30, 2016 | -33.63 Mn |
| Jun 30, 2016 | -40.61 Mn |
| Mar 31, 2016 | -35.44 Mn |
| Dec 31, 2015 | -32.93 Mn |
| Sep 30, 2015 | -26.02 Mn |
| Jun 30, 2015 | -29.36 Mn |
| Mar 31, 2015 | -23.27 Mn |
| Dec 31, 2014 | 35.37 Mn |
| Sep 30, 2014 | -18.32 Mn |